BANCO SANTANDER S.A. (SAN)
Press Release: ESCMID: Sanofis Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
Press Release: ESCMID: Sanofis Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
📈 **POSITIVE** • Medium confidence analysis (62%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (86%) **Content type:** Clinical